tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mason Carrico, 70 are a BUY (87.5%), 10 are a HOLD (12.5%).
Analyst Mason Carrico, currently employed at STEPHENS, carries an average stock price target met ratio of 57.87% that have a potential upside of 31.77% achieved within 193 days.
Mason Carrico’s has documented 161 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NTRA, Natera at 13-Nov-2025.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for CDNA (CAREDX) at 4/17/2024. The price target of $15 was fulfilled within 27 days with a profit of $6.72 (81.16%) receiving and performance score of 30.06.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 30-Apr-2021
$52
$22.79 (78.02%)
$35
1 months 12 days ago
(12-Jan-2026)
5/9 (55.56%)
$12.34 (31.11%)
348
Buy Since 03-Sep-2021
$50
$20.79 (71.17%)
$37
2 months 2 days ago
(22-Dec-2025)
6/9 (66.67%)
$8.61 (20.80%)
404
Buy Since 19-Aug-2019
$50
$20.79 (71.17%)
$30
2 months 12 days ago
(12-Dec-2025)
4/5 (80%)
$11.37 (29.43%)
147
Buy Since 19-Aug-2019
$38
$8.79 (30.09%)
$32
3 months 20 days ago
(04-Nov-2025)
11/14 (78.57%)
$6.37 (20.14%)
384
Buy Since 09-Mar-2021
$41
$11.79 (40.36%)
$37
3 months 20 days ago
(04-Nov-2025)
9/16 (56.25%)
$9.37 (29.62%)
325
Which stock is Mason Carrico is most bullish on?
Which stock is Mason Carrico is most reserved on?
What Year was the first public recommendation made by Mason Carrico?
